24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
How to Make Your Child's Hospital Stay Safer, Less StressfulObesity May Boost Odds for MS in KidsHealth Tip: Diarrhea in KidsOpioid Epidemic Doubled Number of U.S. Kids Sent to Foster CareSwimming Lessons a Must for EveryoneHow to Help When Your Child Weighs Too MuchHave Kids, Buy More Produce?Zika's Damage Continues in Children Infected Before BirthCDC Warns of Start to 'Season' for Mysterious Paralyzing Illness in KidsParent Who Listens Can Help Kids Thrive Despite TraumaHealth Tip: Ear Piercing For KidsReacting Against a 'Too Clean' World, Some Parents Go Too Far the Other WaySurvey Urges Grandparents to Lock Down Their Meds When Kids VisitCalifornia Took on Anti-Vaxxers, and WonHow Does Sunshine During Pregnancy Affect Learning?Surgery Helps Babies Missing a Heart Chamber Survive, But Problems LingerAbuse, Injury More Likely When Child is With Male Caregiver: StudyHow to Foster Your Child's ImaginationLow Vitamin D at Birth Linked to Kids' High Blood Pressure RiskHow Do Kids Learn To Turn Off Troublesome Tics?Meet 'Huggable,' the Robot Bear Who's Helping Hospitalized KidsWill Video Games Make Your Kid Obese? Maybe NotChildhood Brain Tumor Survivors Face More StrugglesFDA Expands Cystic Fibrosis Treatment Approval to Children Ages 6 to 12New Drug Combats Leading Cause of DwarfismHow Do Birth Defects Affect Childhood Cancer Risk?FDA Approves Victoza Injection for Children 10 Years and OlderHealth Tip: Preparing Your Child For Sleepaway CampTips for Keeping Your Child Healthy at CampA Simple Way to Help Prevent Child ObesityType 1 Diabetes Might Affect Young Kids' Brain DevelopmentHow to Put Limits on Your Family's Screen TimeChickenpox Vaccine Shields Kids From Shingles, TooWhooping Cough Vaccine Effectiveness Fades With Time: StudyHundreds of Young Kids Drown in Pools Each Year -- Keep Yours SafeWhich Dogs Are More Likely to Bite Your Kids?Health Tip: Preventing Swimmer's EarAHA News: With Summer Vacation Here, How Much Screen Time Is Too Much?Health Tip: Prevent BullyingHealth Tip: Avoid Mouth Injuries in ChildrenKids Still Being Poisoned by Detergent PodsViolent Video Games, Unlocked Guns a Dangerous Combo for KidsWhy Some Kids With Eczema Are at Higher Allergy Risk'Controlled Burns' Better for Kids' Health Than Wildfires: StudyHow Kids Benefit From Doing ChoresAHA News: Report Seeks Answers About Mysterious, Dangerous Heart Disease in KidsKids of Opioid-Using Parents May Be More Likely to Attempt SuicideCholesterol Levels Improving Among U.S. KidsEarlier Bedtimes Help Kids Fight Obesity1 in 5 Kids Don't Strap on Helmets Before Biking
Questions and AnswersLinks
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Child Development & Parenting: Infants (0-2)
Child Development & Parenting: Early (3-7)

FDA Approves Victoza Injection for Children 10 Years and Older


HealthDay News
Updated: Jun 18th 2019

new article illustration

TUESDAY, June 18, 2019 (HealthDay News) -- Victoza (liraglutide) injection is now approved to treat type 2 diabetes in children 10 years and older, the U.S. Food and Drug Administration announced.

Approved to treat type 2 diabetes in adults in 2010, Victoza is the first noninsulin drug to be approved to treat type 2 diabetes in children since metformin in 2000. Victoza's labeling states that the injection is not a substitute for insulin and is not indicated for patients with type 1 diabetes or those with diabetic ketoacidosis. Dosage of Victoza in children should start at 0.6 mg daily for at least one week. The manufacturer's prescribing information indicates that if additional glycemic control is required, the dose should be increased to 1.2 mg daily, and then to 1.8 mg daily after at least one week of treatment with the 1.2-mg daily dose if additional control is still required.

Approval of Victoza in children aged 10 years and older was based on several placebo-controlled trials in adults and one placebo-controlled trial in children. In the trial of 134 children aged 10 years and older, at 26-week follow-up, HbA1c levels reduced to less than 7 percent for approximately 64 percent of children treated with Victoza compared with 37 percent of children treated with placebo. Researchers found similar results when patients were also taking insulin simultaneously.

Although Victoza has been indicated to reduce the risk for major adverse cardiovascular events in adults with type 2 diabetes, the FDA notes that the drug's effect on major adverse cardiovascular events in children has not been studied, and it is therefore not indicated to reduce the risk for these events in children. Children aged 10 years and older who are taking Victoza have an increased risk for hypoglycemia even without additional therapies for diabetes. Due to an increased risk for thyroid C-cell tumors, Victoza is contraindicated in patients who have had medullary thyroid carcinoma, those with family members who have had medullary thyroid carcinoma, and patients with multiple endocrine neoplasia syndrome type 2.

Approval of Victoza was granted to Novo Nordisk.

More Information